Blueprint Medicines Corporation was removed from the S&P Biotechnology Select Industry Index, effective July 16, 2025. This change is a direct result of the company's pending acquisition by Sanofi.
In addition to the Biotechnology Select Industry Index, Blueprint Medicines was also dropped from the S&P Global BMI Index and the S&P TMI Index on the same date. These removals are standard procedures following a definitive acquisition agreement.
The removal from these indices reflects the company's transition from an independent publicly traded entity. This event is a procedural step in the acquisition process, indicating the progression towards the finalization of the deal with Sanofi.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.